YouTube Facebook LinkedIn Google+ Twitter Xinginstagram rss  

ImClone's Sam Waksal has IPO Plans

September 4, 2013 | ImClone's Sam Waksal is making biotech plans again. Hoping to cash in on biotech's current success, Waksal is planning to spin out two units of his Kadmon Corp that focus on gene therapy and metabolomics and start a Chinese subsidiary. Bloomberg
View Next Related Story
Click here to login and leave a comment.  


Add Comment

Text Only 2000 character limit

Page 1 of 1

For reprints and/or copyright permission, please contact Angela Parsons, 781.972.5467.